Positive Outlook for UK Biotech Jobs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Positive Outlook for UK Biotech Jobs


ePT--the Electronic Newsletter of Pharmaceutical Technology

A significant increase in the recruitment of contract staff is expected during the next 12 months in the UK biotechnology sector, according to a survey conducted by SRG, which provides personnel to various science-based sectors.

“The results of our latest survey clearly show that the outlook for 2010 is looking positive as, from all the sectors surveyed, biotechnology is predicting the second-highest increased permanent staff recruitment during 2010,” Ena Vieira, a biotechnology industry specialist for SRG, explained in a press statement.

The largest increase in staff recruitment is expected to come from the oil, gas, and petrochemicals sector. However, nearly three times as many companies as in 2009 have forecast an increased requirement for permanent staff in 2010, according to the survey. In general, SRG expects recruitment in industries across the board to be stable for the next 12 months.

This outlook is much brighter than that of 2009, when the UK science-labor market cut both permanent and contract staff.

Vieira said, “With the unstable economic situation over the last 12 months, biotech companies have become even more focused on the commercial returns of their products. This has led to a trend emerging, showing that they are now seeking to recruit more commercially focused staff whilst still requiring them to have suitable scientific skills.”

The survey was completed by more than 550 UK employers of scientists, including biotechnology, food, chemicals, pharmaceuticals, oil, petrochemical and healthcare companies, research institutes, and government departments.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here